Alzheimer's drug MK-1167 gets first human test in healthy volunteers

NCT ID NCT07334860

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested two different forms of MK-1167, an experimental drug aimed at treating Alzheimer's symptoms, in 16 healthy adults. Researchers measured how the drug moves through the body and checked for safety. The goal is to find a safe dose before testing it in people with Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MK-1167

What this could lead to

If successful, this study could help determine a safe dose of MK-1167 for future trials in people with Alzheimer's disease.

What could go wrong

This is a very early, small study in healthy people, not patients. It only measures how the drug behaves in the body, not whether it works for Alzheimer's. Many drugs fail in later stages.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • QPS-MRA, LLC ( Site 0001)

    South Miami, Florida, 33143, United States